Executive summary
US Patent 10,017,762 is a method-of-treatment patent for lupus nephritis using an IgE antagonist antibody (or fragment) that reduces IgE expression or biological activity, with dependent claim coverage expanding to reductions in autoreactive IgE/immune complexes and basophil activation biomarkers, plus combination with standard lupus nephritis regimens. The independent scope is broad at the level of “any” IgE antagonist antibody/fragment that selectively binds IgE and ameliorates lupus nephritis, but it is also tethered to (i) lupus nephritis as the therapeutic indication and (ii) functional outcomes tied to IgE biology and basophil activation. Practically, the enforceability risk for a challenger is front-loaded on claim construction (IgE antagonist vs neutralization vs receptor blocking; “reduces expression or biological activity” and “effectuates amelioration”), proof of infringement (use in lupus nephritis patients with an IgE antagonist antibody), and obviousness-type constraints driven by the pre-existing IgE allergy literature and the known role of basophils and IgE in autoimmune settings.
H1: US Patent 10,017,762 claims analysis and US patent landscape for IgE antagonist treatment of lupus nephritis
What is US Patent 10,017,762 claim scope for treating lupus nephritis with an IgE antagonist antibody?
Plain claim capture
US 10,017,762 claim 1 covers a treatment method: administer an “effective amount” of an IgE antagonist antibody (or fragment) that selectively binds IgE and reduces IgE expression or biological activity, resulting in amelioration of lupus nephritis.
Key claim elements
- Indication: “treating lupus nephritis” in a subject in need.
- Active: an antibody or fragment that selectively binds IgE and is an IgE antagonist.
- Mechanism language:
- reduces “expression or biological activity” of IgE, OR
- effectuates “amelioration” of lupus nephritis (functional outcome).
- Administration: “effective amount” administration (no fixed dose or route stated in the excerpts).
Critical interpretive pressure points
- “IgE antagonist” scope: the claim does not name a specific mechanism (e.g., IgE binding block of FcεRI, blockade of CD23, preventing IgE-CD receptor interactions, or downstream signaling). For infringement defenses, accused products can argue that they are not “IgE antagonists” under the ordinary meaning or under the patent’s specification.
- “Reduces expression or biological activity”: many IgE biologics bind circulating IgE and neutralize functional activity but do not reduce “expression” in a strict gene-regulation sense. A challenger could press for constraining construction requiring reduction of functional activity (not gene expression) if the spec emphasizes that interpretation.
- “Effectuates amelioration”: outcome-based language increases evidentiary burden for infringement and post-grant validity challenges. For a method claim, actual clinical benefit in lupus nephritis patients using the asserted agent is central to infringement and inducement proof.
H3: What dependent claims expand claim 1’s IgE antagonist coverage?
- Claim 2 narrows/clarifies the functional endpoints: reduction of at least one of:
- autoreactive IgE levels,
- circulating immune complex levels,
- basophil activation,
- combinations.
- Claim 3 adds a patient-enrichment concept: subject has elevated IgE levels.
- Claims 4-5 provide antibody format constraints:
- claim 4: monoclonal antibody,
- claim 5: humanized monoclonal antibody.
Implication
Dependent claims tighten the “what” (mAb vs humanized mAb) and the “how” (IgE/immune complex/basophil endpoints), creating layered claim coverage that can support infringement under broader claim construction (independent) and narrower proof under dependent claims.
How does claim 7 change the mechanism focus to basophils in US 10,017,762?
Plain claim capture
Claim 7 covers a treatment method where the administered agent decreases basophil number/activity or reduces basophil activation, where the agent is the same class: an antibody/fragment that selectively binds IgE and is an IgE antagonist, effectuating amelioration of lupus nephritis.
Why this matters
- It reframes the mechanism from IgE-centric to basophil-centric outcomes (number/activity/activation).
- This can be used to argue infringement when an accused IgE antagonist drives basophil deactivation in lupus nephritis, even if the accused antibody does not clearly fit a disputed interpretation of “IgE expression reduction.”
H3: What biomarkers are claimed for basophil activation in claim 8?
Claim 8 requires reduction in at least one or more of:
- CD203c expression,
- CD62L,
- HLA-DR.
Critical construction pressure
- Biomarker claims are often used to bolster mechanistic plausibility and support non-obviousness. For infringement, the asserted method typically needs a nexus: did the accused regimen reduce those markers in the lupus nephritis subject population? If the accused program does not measure or report these markers, it can complicate proof of “reduces” within infringement and could create post-grant challenge lines on enablement or written description tied to those specific markers.
H3: What do claims 9-10 add to claim 7?
- Claim 9: monoclonal antibody.
- Claim 10: humanized monoclonal antibody.
What does US Patent 10,017,762 cover for combination therapy with standard lupus nephritis agents?
Claim 6 adds a combination treatment option: the method further comprises administering an agent selected from:
- NSAIDs
- hydroxychloroquine
- corticosteroids
- cyclophosphamide
- azathioprine
- methotrexate
- mycophenolate
- belimumab
- dehydroepiandrosterone
- rituximab
Critical value of the combination language
- It does not require any specific sequencing or dosing overlap in the excerpted text.
- It likely captures most standard-of-care background therapy, making “design-around” by avoiding coadministration ineffective. A generic or biosimilar entry that uses an IgE antagonist could still infringe method claims if background lupus nephritis therapies fall into the listed set.
What IgE antagonists are likely implicated by the patent claim language?
The claims do not name a specific IgE antibody. In US patent landscape practice, enforcement and infringement analysis for antibody method claims typically focus on:
- anti-IgE antibodies (blocking IgE binding to receptors such as FcεRI),
- humanized IgE-neutralizing antibodies or fragments that qualify as an IgE antagonist,
- any antibody that selectively binds IgE and mechanistically prevents IgE-driven immune activation and basophil function.
Practical consequence
If the patent’s specification ties the method to a particular IgE antagonist (commonly the class leader in the anti-IgE space), the effective scope of infringement can tighten beyond “any” IgE antagonist during claim construction and validity analysis. If it does not, independent claim 1 and claim 7 can be broader, raising leverage for the patent holder.
What patent estate and prior art arguments most affect validity for US 10,017,762?
Without the full specification, a complete enumeration of all cited patents cannot be produced from the excerpt alone. Still, the claim structure strongly signals three patentability pressure zones that typically decide outcomes for this type of method claim:
1) Obviousness over IgE biology plus lupus nephritis or autoimmune basophil activation
For a challenger, the core argument is that:
- IgE antagonists and anti-IgE biology were known in allergic disease, with extensive documentation of basophil suppression and immune-complex effects.
- Basophils and IgE signaling were known in immune activation contexts.
- Applying an IgE antagonist to lupus nephritis could be characterized as predictable optimization unless the patent demonstrates a specific lupus nephritis effect tied to the claimed endpoints.
For the patent owner, the counter is typically:
- lupus nephritis is a distinct indication with distinct immunopathology and responder patterns,
- the claimed biomarkers and lupus nephritis amelioration are not taught in the prior art for IgE antagonist monotherapy or in the particular method-of-use context.
2) Written description and enablement for the biomarker limitations (claim 8)
Because claim 8 requires CD203c, CD62L, and HLA-DR reductions, the patent must support these biomarkers in lupus nephritis subjects receiving the IgE antagonist, with enough detail for a skilled person to practice the invention across the claim scope.
If the experimental support in the specification is limited (e.g., only CD203c, no HLA-DR), validity challenges can target whether the patent conveys possession of the full biomarker set.
3) Indefiniteness or overly broad “expression or biological activity” language (claim 1)
Challengers often press for whether “reduces expression” is enabled across antibody mechanisms that only neutralize circulating IgE. The patent owner can counter that “biological activity” is sufficient and “expression” is not a separate required mechanism, but that depends heavily on claim construction and specification wording.
When does US Patent 10,017,762 likely expire, and what exclusivity layers could extend it?
An expiration calculation cannot be completed without the patent’s filing date and priority chain, and without any term adjustment or terminal disclaimer details. The excerpt provides none of that. A complete and accurate exclusivity timeline therefore cannot be produced from the provided information.
What Orange Book status or FDA exclusivity can apply to US 10,017,762?
Because the claims are methods tied to an antibody/fragment and mention humanized monoclonal antibodies, the likely regulatory regime is biologics (BLA/biologic license application), not an Orange Book “small-molecule” listing. Orange Book status is not inferable from the excerpt alone.
A complete and accurate “Orange Book status” answer cannot be produced without the FDA product association for the IgE antagonist referenced by the patent’s specification and prosecution history.
What biosimilar or generic entry risks exist if an IgE antagonist reaches or is used in lupus nephritis?
Risk framing
- Method-of-treatment claims on an antibody do not map to “generic” manufacture in the same way as small-molecule product claims. For antibodies, the legal risk is typically:
- infringement by the biosimilar applicant’s intended use labeling (induced infringement),
- infringement by clinical administration of the biosimilar for the patented method in the US.
- If the claims cover any IgE antagonist antibody/fragment, labeling carve-outs become crucial.
Design-around levers that matter
- Indication restriction: avoiding lupus nephritis in prescribing information for the accused product could reduce induced infringement exposure.
- Mechanism differentiation: if an alternative IgE modality is not an “IgE antagonist” under claim construction, infringement becomes contestable.
- Endpoint/basophil biomarker limitation: if clinical development does not measure those biomarkers and if there is no evidence that the method “reduces” them in a lupus nephritis context, infringement proof can be harder.
Which patent litigation or PTAB challenges are typically relevant to US 10,017,762 type claims?
For US method patents around antibody mechanisms, the common high-stakes dispute pathways are:
- District court infringement actions tied to clinical use and labeling.
- Inter partes review (IPR) or post-grant review (PGR) challenging validity on obviousness and written description/enablement.
A complete list of litigation involving US 10,017,762 cannot be created from the excerpt alone.
How strong is the patent estate for this lupus nephritis-IgE antagonism concept?
Strength must be tied to claim construction and the evidentiary record in the specification plus the breadth of prior art. The excerpt shows a claim that is:
- broad in the agent definition (any IgE antagonist antibody/fragment that selectively binds IgE),
- broad in indication (lupus nephritis generally),
- narrowing via dependent biomarkers and patient enrichment (elevated IgE levels; CD203c/CD62L/HLA-DR reductions),
- enforceable through combination-with-standard-therapy language.
Critical take
The enforceability advantage for the patent holder is the combination of broad independent method coverage plus dependent claim hooks into specific mechanistic endpoints. The counterpressure is typical for antibody method-of-use inventions: if the prior art teaches anti-IgE effects on basophils and immune complexes, a challenger can frame lupus nephritis as an obvious therapeutic extension unless the patent’s experimental showing is clearly distinguishing.
Key claim-by-claim infringement and validity mapping (US 10,017,762 excerpt)
| Claim |
Method anchor |
Agent constraints |
Functional/biomarker constraints |
Infringement proof burden (practical) |
Main validity attack theme |
| 1 |
Treat lupus nephritis by administering IgE antagonist |
Antibody or fragment selectively binds IgE; IgE antagonist |
Reduces IgE expression or biological activity; ameliorates LN |
Show accused therapy is an IgE antagonist and used to ameliorate LN |
Obviousness from anti-IgE biology + LN treatment predictability; construction of “antagonist” and “expression” |
| 2 |
Same as 1 |
Same |
Reduces autoreactive IgE/immune complexes/basophil activation |
Show reduction of at least one endpoint in LN patients |
Written description/enablement if endpoints not supported across scope; obviousness if endpoints known |
| 3 |
Same |
Same |
Elevated IgE levels in subject |
Demonstrate patient selection based on elevated IgE |
Enablement/obviousness if “elevated IgE” selection not taught |
| 4 |
Same |
Monoclonal antibody |
None beyond claim 1 |
Show accused antibody is monoclonal |
Narrower, less attack surface unless accused uses non-mAb format |
| 5 |
Same |
Humanized monoclonal antibody |
None beyond claim 4 |
Show humanized status |
Easier to design around if non-humanized antibody exists (scope depends on how “humanized” is construed) |
| 6 |
Same |
Adds combinations |
None beyond claim 1 |
Show background therapy includes listed agents with accused IgE antagonist |
If standard-of-care already known, combine language may not save non-obviousness |
| 7 |
Treat lupus nephritis by administering IgE antagonist that targets basophils |
Same agent class |
Decreases basophil number/activity or basophil activation |
Show LN treatment reduces basophil activation |
Obviousness if basophil suppression known for anti-IgE |
| 8 |
Same |
Same |
Reduces CD203c, CD62L, HLA-DR |
Marker reduction in LN patients |
Written description/enablement if only partial marker support |
| 9 |
Same as 7 |
Monoclonal antibody |
None beyond claim 7 |
mAb format |
Narrower, depends on accused format |
| 10 |
Same as 9 |
Humanized monoclonal antibody |
None beyond claim 9 |
Humanized status |
“Humanized” scope, design-around through different antibody engineering |
What competitive landscape questions determine commercial risk for US 10,017,762?
- Is an IgE antagonist actually in lupus nephritis trials or used off-label? If yes, infringement risk depends on the antibody class and whether the clinical effect maps to the claim’s “amelioration” and basophil/IgE/immune complex reductions.
- Does the biosimilar labeling strategy include lupus nephritis or a basophil-related endpoint rationale? Labeling drives induced infringement exposure.
- How central are CD203c/CD62L/HLA-DR in the development plan? If the sponsor does not measure these markers, the evidence record for claim 8 may be weaker, but claim 1 and claim 7 still remain.
Key Takeaways
- US 10,017,762 is a lupus nephritis method-of-treatment patent built around administering an IgE antagonist antibody/fragment that selectively binds IgE and ameliorates lupus nephritis.
- Dependent claims support infringement leverage through functional endpoints (autoreactive IgE, immune complexes, basophil activation) and specific basophil activation biomarkers (CD203c, CD62L, HLA-DR).
- Combination claim language (claim 6) aligns the patent with standard lupus nephritis regimens, reducing the effectiveness of “avoid combination therapy” design-arounds.
- Validity risk for the patent holder is concentrated in obviousness based on known anti-IgE suppression of basophils and immune activation, unless the specification shows lupus nephritis-distinguishing evidence and supports the biomarker claims across the method scope.
- Commercial infringement risk is mainly driven by whether an accused IgE antagonist is used in lupus nephritis in the US and whether outcomes and patient selection align with the claim requirements.
FAQs
1) Does US 10,017,762 require reduction of IgE gene expression, or is neutralizing IgE activity enough?
The claim text includes both “expression or biological activity,” with “biological activity” often aligning better with neutralizing IgE binding effects. Construction depends on claim interpretation against the specification.
2) Would administering an IgE antagonist for lupus nephritis automatically infringe claim 1 even if basophils are not measured?
For claim 1, infringement is tethered to amelioration of lupus nephritis and reduction of IgE expression/biological activity. Claim 8 requires specific biomarker reductions, but independent claim 1 does not.
3) What is the strongest design-around: changing the antibody engineering, changing the indication, or changing endpoints?
Changing indication labeling away from lupus nephritis is typically most protective; engineering changes may work only if the product is no longer an “IgE antagonist” under claim construction or no longer “selectively binds IgE” as required.
4) How do the “humanized monoclonal” limitations in claims 5 and 10 affect infringement risk?
They create a narrower subset coverage. If an accused product is not humanized (or is construed not to be “humanized”), those dependent claims can be harder to reach, but independent claims 1 and 7 may still apply unless the humanized limitation is treated as an implicit requirement via construction.
5) Does the combination clause in claim 6 expand infringement exposure for background therapy?
It can. If accused IgE antagonist treatment is given alongside any of the listed standard agents, claim 6 can be implicated without needing any special sequencing, provided the rest of claim 1 or claim 7 is satisfied.
References
- US Patent 10,017,762. “Method of treating lupus nephritis using an IgE antagonist antibody.” United States Patent and Trademark Office. (Claims excerpt provided in prompt).
